{
    "organizations": [],
    "uuid": "df084748df99508c99ae38c6fe732600bac309b0",
    "author": "cnbc.com",
    "url": "http://www.cnbc.com/2018/05/09/globe-newswire-bio-path-holdings-to-announce-first-quarter-2018-financial-results-on-may-16-2018.html",
    "ord_in_thread": 0,
    "title": "Bio-Path Holdings to Announce First Quarter 2018 Financial Results on May 16, 2018",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "HOUSTON, May 09, 2018 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize ® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced that it will host a live conference call and audio webcast on Wednesday, May 16, 2018 at 8:30 a.m. ET to report financial results for the first quarter ended March 31, 2018 and to provide a business overview.\nTo access the live conference call, please call (844) 815-4963 (domestic) or (210) 229-8838 (international) at least five minutes prior to the start time and refer to conference ID 1096178. A live audio webcast of the call will also be available on the Presentations section of the Company’s website, www.biopathholdings.com . An archived webcast will be available on the Bio-Path website approximately two hours after the event.\nAbout Bio-Path Holdings, Inc.\nBio-Path is a biotechnology company developing DNAbilize ® , a novel technology that has yielded a pipeline of RNAi nanoparticle drugs that can be administered with a simple intravenous transfusion. Bio-Path’s lead product candidate, prexigebersen (BP1001, targeting the Grb2 protein), is in a Phase 2 study for blood cancers and in preclinical studies for solid tumors. This is followed by BP1002, targeting the Bcl-2 protein, which the company anticipates entering into clinical studies where it will be evaluated in lymphoma and solid tumors.\nFor more information, please visit the Company's website at http://www.biopathholdings.com .\nContact Information:\nInvestors\nWill O’Connor\nStern Investor Relations\n212-362-1200\nwill@sternir.com\nDoug Morris\nInvestor Relations\nBio-Path Holdings, Inc.\n832-742-1369\nSource:Bio-Path Holdings, Inc.",
    "published": "2018-05-09T16:00:00.000+03:00",
    "crawled": "2018-05-09T16:22:25.004+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "houston",
        "may",
        "globe",
        "newswire",
        "holding",
        "nasdaq",
        "bpth",
        "biotechnology",
        "company",
        "leveraging",
        "proprietary",
        "dnabilize",
        "antisense",
        "rnai",
        "nanoparticle",
        "technology",
        "develop",
        "portfolio",
        "targeted",
        "nucleic",
        "acid",
        "cancer",
        "drug",
        "today",
        "announced",
        "host",
        "live",
        "conference",
        "call",
        "audio",
        "webcast",
        "wednesday",
        "may",
        "et",
        "report",
        "financial",
        "result",
        "first",
        "quarter",
        "ended",
        "march",
        "provide",
        "business",
        "overview",
        "access",
        "live",
        "conference",
        "call",
        "please",
        "call",
        "domestic",
        "international",
        "least",
        "five",
        "minute",
        "prior",
        "start",
        "time",
        "refer",
        "conference",
        "id",
        "live",
        "audio",
        "webcast",
        "call",
        "also",
        "available",
        "presentation",
        "section",
        "company",
        "website",
        "archived",
        "webcast",
        "available",
        "website",
        "approximately",
        "two",
        "hour",
        "event",
        "holding",
        "biotechnology",
        "company",
        "developing",
        "dnabilize",
        "novel",
        "technology",
        "yielded",
        "pipeline",
        "rnai",
        "nanoparticle",
        "drug",
        "administered",
        "simple",
        "intravenous",
        "transfusion",
        "lead",
        "product",
        "candidate",
        "prexigebersen",
        "bp1001",
        "targeting",
        "grb2",
        "protein",
        "phase",
        "study",
        "blood",
        "cancer",
        "preclinical",
        "study",
        "solid",
        "tumor",
        "followed",
        "bp1002",
        "targeting",
        "protein",
        "company",
        "anticipates",
        "entering",
        "clinical",
        "study",
        "evaluated",
        "lymphoma",
        "solid",
        "tumor",
        "information",
        "please",
        "visit",
        "company",
        "website",
        "http",
        "contact",
        "information",
        "investor",
        "connor",
        "stern",
        "investor",
        "relation",
        "doug",
        "morris",
        "investor",
        "relation",
        "holding",
        "source",
        "holding",
        "inc"
    ]
}